ArticlePloS one2022

p53 oligomerization status as an indicator of sensitivity of p53-wildtype neuroblastomas to the combination of DNA damaging agent and Chk1 inhibitor.

Aime A Levesque et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.